JP6145352B2 - Antihypertensive agent of fermented makonbu using Bacillus natto - Google Patents
Antihypertensive agent of fermented makonbu using Bacillus natto Download PDFInfo
- Publication number
- JP6145352B2 JP6145352B2 JP2013160805A JP2013160805A JP6145352B2 JP 6145352 B2 JP6145352 B2 JP 6145352B2 JP 2013160805 A JP2013160805 A JP 2013160805A JP 2013160805 A JP2013160805 A JP 2013160805A JP 6145352 B2 JP6145352 B2 JP 6145352B2
- Authority
- JP
- Japan
- Prior art keywords
- fermented
- blood pressure
- bacillus natto
- makonbu
- macomb
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 244000063299 Bacillus subtilis Species 0.000 title claims description 21
- 235000014469 Bacillus subtilis Nutrition 0.000 title claims description 21
- 239000002220 antihypertensive agent Substances 0.000 title description 15
- 229940030600 antihypertensive agent Drugs 0.000 title description 15
- 230000036772 blood pressure Effects 0.000 claims description 29
- 235000013305 food Nutrition 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 9
- 235000013376 functional food Nutrition 0.000 claims description 8
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 18
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 18
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 18
- 230000000694 effects Effects 0.000 description 15
- 230000002401 inhibitory effect Effects 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000012153 distilled water Substances 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 102000005862 Angiotensin II Human genes 0.000 description 6
- 101800000734 Angiotensin-1 Proteins 0.000 description 6
- 102400000344 Angiotensin-1 Human genes 0.000 description 6
- 101800000733 Angiotensin-2 Proteins 0.000 description 6
- 206010020772 Hypertension Diseases 0.000 description 6
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 6
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 6
- 229950006323 angiotensin ii Drugs 0.000 description 6
- 235000013361 beverage Nutrition 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 241001474374 Blennius Species 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 230000003276 anti-hypertensive effect Effects 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 235000013557 nattō Nutrition 0.000 description 4
- 230000035488 systolic blood pressure Effects 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 2
- 102000004881 Angiotensinogen Human genes 0.000 description 2
- 108090001067 Angiotensinogen Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000007530 Essential hypertension Diseases 0.000 description 2
- 241000199919 Phaeophyceae Species 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000015140 cultured milk Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- -1 elixirs Substances 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 210000002464 muscle smooth vascular Anatomy 0.000 description 2
- 239000000820 nonprescription drug Substances 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000002889 sympathetic effect Effects 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000012431 wafers Nutrition 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010013647 Drowning Diseases 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 241000206572 Rhodophyta Species 0.000 description 1
- 241000269851 Sarda sarda Species 0.000 description 1
- 201000004239 Secondary hypertension Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000002160 alpha blocker Substances 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229940125364 angiotensin receptor blocker Drugs 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000005037 parasympathetic nerve Anatomy 0.000 description 1
- 230000036513 peripheral conductance Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 108091006082 receptor inhibitors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 235000021012 strawberries Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
Images
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Description
本発明は納豆菌Bacillus subtilius nattoを用いたマコンブ発酵物を有効成分として含有する血圧上昇抑制作用に関する。本発明は、血圧上昇抑制機能性食品または食品素材、内服剤として、ヒト若しくはヒト以外の動物に与えられる医薬品(動物用治療薬も含む)用、飲食品用、および飼料用またはペットフードの組成物を意味する。The present invention relates to an antihypertensive action comprising a fermented makonbu product using Bacillus subtilis NATTO as an active ingredient. The present invention relates to a blood pressure increase-suppressing functional food or food material, or an internal preparation for pharmaceuticals (including animal therapeutics) given to humans or animals other than humans, for foods and drinks, and for feeds or pet foods. Means a thing.
高血圧は生活習慣病の一つである。高血圧は原因が分かっている二次性高血圧と原因がわからない本態性高血圧の二つがあるが、日本における高血圧患者の約90%が本態性高血圧である。血圧は、心拍出量と末梢血管抵抗その他さまざまな因子によって調節されており、なかでも、レニン・アンジオテンシン系は、血圧の制御に関して大きな役割を担っている。肝臓でアンジオテンシノーゲンが合成され、アンジオテンシノーゲンは腎臓で合成されるレニンによってアンジオテンシンIに変換される。さらにアンジオテンシン変換酵素(ACE)によってアンジオテンシンIIへと変換される。アンジオテンシンIIがアンジオテンシンII受容体に結合することで、血管平滑筋が収縮し、結果として血圧が上昇する。高血圧は自覚症状がないため、放置してしまうことが多く、動脈硬化、心臓病、脳卒中を引き起こすことがある。Hypertension is one of lifestyle-related diseases. There are two types of hypertension: secondary hypertension whose cause is known and essential hypertension whose cause is unknown. About 90% of hypertensive patients in Japan have essential hypertension. Blood pressure is regulated by various factors such as cardiac output, peripheral vascular resistance, and the renin-angiotensin system plays a major role in controlling blood pressure. Angiotensinogen is synthesized in the liver, and angiotensinogen is converted to angiotensin I by renin synthesized in the kidney. Furthermore, it is converted into angiotensin II by angiotensin converting enzyme (ACE). By binding angiotensin II to the angiotensin II receptor, vascular smooth muscle contracts, resulting in an increase in blood pressure. Hypertension has no subjective symptoms and is often left unattended, which can cause arteriosclerosis, heart disease, and stroke.
前述の高血圧については、これを解消するための医療品が種々提案され、既に数多く市販されている。治療剤としては、腎臓でのナトリウムと水の再吸収を抑制し循環血液量を減少させて血圧を下げる利尿薬、交感神経のα受容体の血管収縮作用を遮断し血管を拡張させ血圧を下げるα遮断薬、交感神経のβ受容体の心臓収縮力強化や昇圧ホルモン産生などの作用を遮断して血圧を下げるβ遮断薬、カルシウムイオンの細胞内への取り込みを抑制し血管を拡張することで血圧を下げるカルシウム拮抗薬、強力な昇圧ホルモンであるアンジオテンシンIIの生産を減少させ、血圧を下げるACE阻害薬、昇圧ホルモンであるアンジオテンシンIIが作用する受容体の働きを阻害することで血圧を下げるアンジオテンシンII受容体阻害薬(ARBが用いられるが、これら医療用合成製剤は、処方箋を必要とするため、簡易には入手できないばかりか、製剤の投与又は服用により種々の副作用を伴うことがある。従って、高血圧の治療に使用される抗高血圧剤として、入手が容易でかつ副作用ができるだけ少ない天然物起源のものが求められている。天然物起源の高血圧の改善剤としては、ACE阻害を示すノリ、カツオ、ワカメなどのペプチド、副交感神経を刺激し血管平滑筋が弛緩され血圧が降下作用を示す杜中葉抽出物、ノルアドレナリンの分泌を抑制し血圧降下作用を示すγ−アミノ酪酸を配合特定保健用食品が知られており、これらは特定保健用食品としての承認を得ている。Regarding the above-mentioned hypertension, various medical products for solving this problem have been proposed and many are already on the market. Therapeutic agents are diuretics that suppress the reabsorption of sodium and water in the kidneys and reduce the blood circulation to lower blood pressure, block the vasoconstrictive action of sympathetic alpha receptors and dilate blood vessels to lower blood pressure. α-blocker, β-blocker that lowers blood pressure by blocking the effects of sympathetic β-receptor enhancement of cardiac contraction and production of pressor hormones, suppresses calcium ion uptake into cells and dilates blood vessels Calcium antagonist that lowers blood pressure, ACE inhibitor that decreases the production of angiotensin II, a powerful pressor hormone, and angiotensin that lowers blood pressure by inhibiting the action of the receptor that angiotensin II, a pressor hormone acts on II receptor inhibitors (ARBs are used, but these synthetic drugs are not easily available because they require prescriptions. Various side effects may accompany the administration or administration of the preparation, and therefore, anti-hypertensive agents used for the treatment of hypertension are required to be easily obtained and have a natural product origin with as few side effects as possible. Antihypertensive agents such as glue, bonito, seaweed, etc. that inhibit ACE, parasympathetic nerves are stimulated, vascular smooth muscle is relaxed, blood pressure is lowered, and noradrenaline secretion is suppressed. Specific health foods containing γ-aminobutyric acid exhibiting a blood pressure lowering action are known, and these have been approved as foods for specific health.
一方、海藻類のマコンブは褐藻類コンブ目コンブ属の海藻として知られており、コンブ類の中でも肉厚で良質な昆布である。主に北海道道南地方で生産され、養殖の生産量も多く大変なじみ深い海藻である。マコンブから抽出した成分が血糖値上昇抑制作用、抗酸化作用を有することが報告されている。また、マコンブ等特定の褐藻類及び紅藻類から水抽出される成分を含有する薬剤が、魚類の養殖場における細菌感染症による斃死を軽減することが知られている。On the other hand, the seaweed mambu is known as a seaweed belonging to the genus Kombu in the order of brown algae, and is a thick and high quality kelp among the kombu. This seaweed is a very familiar seaweed produced mainly in Hokkaido's southern Hokkaido region, with a large amount of aquaculture. It has been reported that a component extracted from macomb has a blood glucose level increase inhibitory effect and an antioxidant effect. Moreover, it is known that the chemical | medical agent containing the component water-extracted from specific brown algae and red algae, such as a macomb, reduces drowning by the bacterial infection in the fish farm.
本発明の課題は、日常の食生活において容易に入手および摂取でき、血圧上昇を抑制することができる、副作用の少ない予防・改善用機能性食品又は食品素材や、飼料を提供することにある。An object of the present invention is to provide a functional food or food material for prevention and improvement, which can be easily obtained and ingested in daily eating habits, and can suppress an increase in blood pressure, or a feed material, and feed.
本発明者は、上述の目的を達成するために、マコンブの機能性成分と納豆菌の機能性に着目し、鋭意研究を行った結果、納豆菌を用いたマコンブ発酵物10mM Tris−HCl緩衝液(pH8.5)抽出物に血圧上昇抑制作用があることを見出すに至った。In order to achieve the above-mentioned object, the present inventor has paid attention to the functional components of Macombu and the functionality of Bacillus natto, and as a result of intensive studies, the fermented Macombib 10 mM Tris-HCl buffer using Bacillus natto (PH 8.5) It has been found that the extract has an antihypertensive effect.
本発明は、このような知見に基づいて完成されたものである。すなわち、本発明の血圧上昇抑制作用は、いずれもマコンブ発酵物を有効成分とすることを特徴とするものである。The present invention has been completed based on such findings. That is, the antihypertensive action of the present invention is characterized in that the fermented makonbu is an active ingredient.
納豆菌を用いたマコンブ発酵物に含まれる血圧上昇抑制作用を有する物質がいかなる化合物であるかについては、未だその詳細は不明であるが、マコンブ発酵物から10mM Tris−HCl緩衝液(pH8.5)抽出により溶出させた成分が血圧上昇抑制作用を発揮することは実験的に確かめられている。したがって、納豆菌を用いたマコンブ発酵物は、そのまま本発明の血圧上昇抑制作用の構成成分とすることで予防・改善が発現する。Although it is still unclear what kind of compound the substance having an inhibitory effect on blood pressure increase contained in the fermented macomb using Bacillus natto is, the 10 mM Tris-HCl buffer (pH 8.5) is used. ) It has been experimentally confirmed that the components eluted by extraction exert a blood pressure increase inhibitory effect. Therefore, the fermented makonbu using Bacillus natto exhibits prevention and improvement as it is as a constituent component of the blood pressure increase inhibitory action of the present invention.
即ち本発明が提供するのは以下の通りである。That is, the present invention provides the following.
[1]納豆菌を用いたマコンブ発酵物を有効成分として含有する。[1] It contains a fermented makonbu using natto bacteria as an active ingredient.
[2]納豆菌を用いたマコンブ発酵物を含有する組成物を有効成分として含有する血圧上昇抑制剤。[2] An antihypertensive agent comprising, as an active ingredient, a composition containing a fermented makonbu product using Bacillus natto.
[3][1]または[2]に記載の血圧上昇抑制剤からなる機能性食品。[3] A functional food comprising the antihypertensive agent according to [1] or [2].
[4][1]または[2]に記載の血圧上昇抑制剤からなる食品素材。[4] A food material comprising the antihypertensive agent according to [1] or [2].
[5][1]または[2]に記載の血圧上昇抑制剤からなるペットフード。[5] A pet food comprising the antihypertensive agent according to [1] or [2].
[6][1]〜[4]に記載の血圧上昇抑制剤を含有する飲食用組成物。[6] A food and drink composition containing the blood pressure elevation inhibitor according to [1] to [4].
[7][1]〜[4]に記載の血圧上昇抑制剤を含有する医薬用組成物。[7] A pharmaceutical composition comprising the antihypertensive agent according to [1] to [4].
本発明の血圧上昇抑制剤、またはこれを含有する組成物は、体内でアンジオテンシンIを、昇圧作用を持つアンジオテンシンIIに変換するACEの活性を抑制することから、血圧上昇抑制作用が期待できる。従って、血圧上昇抑制に有用である。さらに、食経験のある材料から本発明の剤または組成物を製造することが可能であるので、摂取しても安全である。The antihypertensive agent of the present invention or a composition containing the antihypertensive agent suppresses the activity of ACE that converts angiotensin I into angiotensin II having an antihypertensive action in the body, and therefore an antihypertensive action can be expected. Therefore, it is useful for suppressing blood pressure increase. Furthermore, since it is possible to produce the agent or composition of the present invention from ingredients with food experience, it is safe to take.
本明細書の血圧上昇抑制剤は、納豆菌を用いたマコンブ発酵物を有効成分として含有するACE害作用を有する剤および組成物である。上記の化合物の含有量は限定されないが、血圧上昇抑制作用を発揮できる範囲で含まれていれば良い。The antihypertensive agent of the present specification is an agent and a composition having an ACE harmful action containing a fermented makonbu product using Bacillus natto as an active ingredient. Although content of said compound is not limited, it should just be contained in the range which can exhibit the blood pressure rise inhibitory effect.
本発明の飲食用組成物は、上記の血圧上昇抑制剤を含有する組成物であり、これらを一般的な食品に混合したものである。また、公知の食品として適当な担体や助剤などを使用してカプセル剤、錠剤、顆粒剤など服用しやすい形態にしたものでもよい。ここに言う飲食用とは、例えば、一般食品、保健機能食品(特定保健用食品、栄養機能食品)、健康食品、栄養補助食品、ペットフードなどである。ここにいう一般食品とは、飲料、乳製品、発酵乳、乳酸菌飲料、加工乳、コーヒー飲料、ジュース、アイスクリーム、飴、ビスケット、ウェハース、ゼリー、スープ、麺類、を含むがそれに限定されるものではない。好ましくは飲料、乳製品、加工乳、発酵乳、乳酸菌飲料、ウェハース、ゼリーを含む。The composition for eating and drinking of the present invention is a composition containing the above-mentioned blood pressure increase inhibitor, and these are mixed with general foods. Further, capsules, tablets, granules and the like that are easy to take may be used by using appropriate carriers and auxiliaries as known foods. The food and drink here refers to, for example, general foods, health functional foods (special health foods, nutritional functional foods), health foods, nutritional supplements, pet foods, and the like. General food as used herein includes, but is not limited to, beverages, dairy products, fermented milk, lactic acid bacteria beverages, processed milk, coffee beverages, juices, ice creams, strawberries, biscuits, wafers, jellies, soups, and noodles. is not. Preferably, beverages, dairy products, processed milk, fermented milk, lactic acid bacteria beverages, wafers, and jelly are included.
本発明の医薬用組成物は、上記の血圧上昇抑制剤を含有する組成物であり、上記剤そのものであってもよいし、所望により医薬的に許容される担体を含有する組成物であってもよい。その用途は限定されず、例えば一般用医薬品(OTC)など容易に入手可能な医薬品又は医薬部外品などが挙げられる。医薬用組成物の形態は限定されず、例えば、丸薬剤、液剤、粉末剤、顆粒剤、錠剤、カプセル錠剤、トローチ剤、シロップ剤、ドライシロップ剤などである。好ましくはカプセル剤、液剤、エリクシル、錠剤、カシエ、座薬などとするほうが良い。また医薬的に許容される担体とは、経口、経腸、経皮、および皮下投与のために好適である任意の材料であり、例えば水、ゼラチン、アラビアガム、ラクトース、微結晶性セルロース、スターチ、ナトリウムスターチグリコレート、燐酸水素カルシウム、ステアリン酸マグネシウム、タルク、コロイド性二酸化ケイ素、などが挙げられる。The pharmaceutical composition of the present invention is a composition containing the above antihypertensive agent, may be the above agent itself, or a composition containing a pharmaceutically acceptable carrier as desired. Also good. The use is not limited, and examples thereof include readily available drugs such as over-the-counter drugs (OTC) or quasi drugs. The form of the pharmaceutical composition is not limited, and examples thereof include pills, solutions, powders, granules, tablets, capsule tablets, troches, syrups, and dry syrups. Preferably, capsules, liquids, elixirs, tablets, cachets, suppositories and the like are used. A pharmaceutically acceptable carrier is any material suitable for oral, enteral, transdermal, and subcutaneous administration, such as water, gelatin, gum arabic, lactose, microcrystalline cellulose, starch. Sodium starch glycolate, calcium hydrogen phosphate, magnesium stearate, talc, colloidal silicon dioxide, and the like.
納豆菌を用いたマコンブ発酵物ならびに該組成物は、血圧上昇抑制剤の有効成分として配合されるが、血圧上昇抑制剤として製剤化する場合、剤形としては、粉末状、顆粒状、錠剤状等、任意の剤形を採用することができる。その際、保存や取り扱いを容易にするために、デキストリン、シクロデキストリン等のキャリヤ、保存料、その他任意の助剤を必要に応じて配合することができる。またその形態は限定されず、飲食用組成物、医薬用組成物を含む。これらの含有量は限定されないが、血圧上昇抑制作用に対して効果が発揮できる範囲で含まれていれば良い。The fermented makonbu using natto and the composition are blended as an active ingredient of an antihypertensive agent, but when formulated as an antihypertensive agent, the dosage form is powder, granule, tablet Any dosage form can be employed. At that time, in order to facilitate storage and handling, carriers such as dextrin and cyclodextrin, preservatives and other optional auxiliaries can be blended as necessary. Moreover, the form is not limited, The composition for food and drink and the composition for pharmaceuticals are included. Although these content is not limited, it should just be contained in the range which can exhibit an effect with respect to a blood pressure rise inhibitory effect.
前期血圧上昇抑制剤は、ACEの活性を阻害してアンジオテンシンIIが生成されないようにする。The antihypertensive agent inhibits the activity of ACE so that angiotensin II is not generated.
納豆菌を用いたマコンブ発酵物を有効成分として含有する本発明の血圧上昇の予防・改善用機能性食品又は食品素材は、前記本発明の血圧上昇の予防・改善剤を飲食品原料の一部として用いたり、あるいは製造工程又は製造後に添加・配合することにより得ることができる。かかる機能性食品としては特に制限されるものではなく、調味類、ふりかけ類、菓子類、スナック類、麺類、魚肉練り製品、乳製品、飲料などを具体的に例示することができる。The functional food or food material for preventing or improving blood pressure elevation according to the present invention, which contains a fermented makonbu product using Bacillus natto as an active ingredient, is a part of the raw material for foods and beverages for preventing or improving blood pressure elevation according to the present invention. Or can be obtained by adding and blending after the production process or production. Such functional foods are not particularly limited, and specific examples include seasonings, sprinkles, confectionery, snacks, noodles, fish paste products, dairy products, beverages, and the like.
以下に本発明をより詳細に説明する為に実施例を挙げるが、本発明はこれらによって何ら限定されるものではない。Examples are given below to describe the present invention in more detail, but the present invention is not limited by these.
サンプルは500μm程度に粉砕したマコンブ粉末(北海道道南産)2.5gを50mlの蒸留水に加え、pHを8.0に調整後、加圧加熱滅菌を行った。納豆菌前培養液を500μl接種し、30℃で160rpmで回転振とう培養した。5日間培養後凍結乾燥を行い、マコンブ発酵物1gに100mlの10mM Tris−HCl緩衝液(pH8.5)を添加し、50℃で1時間振とうさせ、温水抽出したものの上清をサンプルとした。The sample was sterilized by autoclaving after adding 2.5 g of macomb powder (produced in Hokkaido, Hokkaido) pulverized to about 500 μm to 50 ml of distilled water and adjusting the pH to 8.0. 500 μl of the Bacillus natto preculture was inoculated and cultured at 30 ° C. and 160 rpm. After culturing for 5 days, lyophilization was carried out, 100 ml of 10 mM Tris-HCl buffer (pH 8.5) was added to 1 g of the macomb fermented product, shaken at 50 ° C. for 1 hour, and extracted with warm water as a sample. .
納豆菌を用いたマコンブ発酵物のACE活性阻害作用に関する検討
納豆菌を用いたマコンブ発酵物のACE活性への影響について、試験管内での酵素反応系を用いて検討した。蒸留水で希釈した各濃度のサンプル溶液10μlを添加し全量を130μl/反応ウェルとした。Examination of ACE activity inhibitory action of fermented macabon using Bacillus natto The influence of fermented macomb using natto bacillus on ACE activity was examined using an enzyme reaction system in a test tube. 10 μl of sample solution of each concentration diluted with distilled water was added to make a total volume of 130 μl / reaction well.
本試験は(株)同仁化学研究所のACE Kit−WSTを使用した。本試験の反応に用いた溶液(A〜C液)は、以下のとおり調製した。A液はキット付属のSubstrate bufferである。B液はキット付属のEnzyme Bを2mlの蒸留水で溶解し、溶解した酵素液1.5mlをキット付属品のEnzyme Aに加え溶解した。C液はキット付属のEnzyme Cを3mlの蒸留水で溶解した。同じくキット付属のCoenzymeを3mlの蒸留水で溶解した。溶解したEnzyme CとCoenzymeをそれぞれ2.8mlずつキット付属のIndicator solutionに添加した。This test used ACE Kit-WST of Dojindo Laboratories. The solutions (A to C solutions) used for the reaction in this test were prepared as follows. A liquid is Substrate buffer attached to the kit. For solution B, Enzyme B attached to the kit was dissolved in 2 ml of distilled water, and 1.5 ml of the dissolved enzyme solution was dissolved in Enzyme A attached to the kit. The solution C was obtained by dissolving Enzyme C attached to the kit with 3 ml of distilled water. Similarly, Coenzyme included in the kit was dissolved in 3 ml of distilled water. Each 2.8 ml of dissolved Enzyme C and Coenzyme was added to the Indicator solution included in the kit.
プレート内でのACE反応は、各濃度に希釈したサンプル10μl、A液10μlとB液10μlを混合し、37℃で1時間プレインキュベーションした。次にC液100μlを加えて室温で10分間インキュベーションすることで実施させた。その後、450nmの吸光度を測定することでACE阻害活性を評価した。コントロールは、サンプルの代わりに各サンプルと同等の10mM Tris−HCl緩衝液(pH8.5)を添加した。各試験区には、B液の代わりにA液を添加したブランクを設定した。
阻害率は以下の計算式から求めた。阻害率=1−(サンプルの吸光度−サンプルのブランクの吸光度)/(コントロールの吸光度−コントロールのブランクの吸光度)。コントロールを100として溶媒と濃度に関連して、相対的のACE阻害率を表2に示した。In the ACE reaction in the plate, 10 μl of sample diluted to each concentration, 10 μl of solution A and 10 μl of solution B were mixed and preincubated at 37 ° C. for 1 hour. Next, 100 μl of solution C was added and incubated at room temperature for 10 minutes. Thereafter, the ACE inhibitory activity was evaluated by measuring the absorbance at 450 nm. As a control, 10 mM Tris-HCl buffer (pH 8.5) equivalent to each sample was added instead of the sample. In each test group, a blank in which solution A was added instead of solution B was set.
The inhibition rate was calculated from the following calculation formula. Inhibition rate = 1- (absorbance of sample-absorbance of sample blank) / (absorbance of control-absorbance of control blank). The relative ACE inhibition rate in relation to the solvent and concentration is shown in Table 2 with respect to 100 as a control.
図1から明らかなように、納豆菌を用いたマコンブ発酵物にACE活性阻害が認められた。阻害のIC50値は、70μg/mlであった。したがって、納豆菌を用いたマコンブ発酵物はACE活性の阻害に有効であることが実証された。As is clear from FIG. 1, ACE activity inhibition was observed in the fermented macomb using Bacillus natto. The IC 50 value for inhibition was 70 μg / ml. Therefore, it was demonstrated that the fermented macomb using Bacillus natto is effective in inhibiting ACE activity.
納豆菌を用いたマコンブ発酵物の血圧上昇抑制試験に関する検討
納豆菌を用いたマコンブ発酵物のACEへの影響について、動物実験においてTail−cuff法を用いて検討した。Study on suppression of blood pressure increase in fermented macomb using Bacillus natto The effect of fermented macomb on ACE using Bacillus natto was examined using the tail-cuff method in animal experiments.
本試験では、温水抽出物を減圧乾固したものサンプルとして用いた。本試験では溶液(A〜B液)は、以下のとおり調整した。A液はサンプル300mgを2mlの蒸留水に溶解した。B液はアンジオテンシンI(和光純薬)4.5mgを10mlの蒸留水に溶解した。In this test, the hot water extract was dried under reduced pressure and used as a sample. In this test, the solutions (A to B solutions) were prepared as follows. As the liquid A, 300 mg of a sample was dissolved in 2 ml of distilled water. For solution B, 4.5 mg of angiotensin I (Wako Pure Chemical Industries, Ltd.) was dissolved in 10 ml of distilled water.
ddYマウス、雄性、5週齢(日本SLC)を固形飼料(MRストック、日本農産工業)で飼育室(25℃±2)にて1週間予備飼育後、1群8匹とし群分けを行った。マウスに蒸留水またはA液を0.4ml経口投与し、腹腔内カニューレを装着後、測定用ケージに入れた。投与から30分後にカフを装着し、マウス・ラット用無加温型非観血式血圧計(BLOOD PRESURE MONITOR FOR MICE&RAT Model MK−2000,室町機械)を使用し、自動で尾動脈血圧を6回測定し、その平均値をアンジオテンシンI投与前収縮期血圧として評価した。腹腔内カニューレを用いてB液を100μl投与した。投与から2分後に同様に血圧を測定し、アンジオテンシンI投与後収縮期血圧とした。アンジオテンシンI投与前と投与後の収縮期血圧の差を血圧上昇値とした。 A ddY mouse, male, 5 weeks old (Japan SLC) was preliminarily raised in a breeding room (25 ° C. ± 2) in a solid feed (MR stock, Nippon Nosan Kogyo) for 1 week, and then divided into 8 groups per group. . The mice were orally administered with 0.4 ml of distilled water or solution A, fitted with an intraperitoneal cannula, and then placed in a measurement cage. Thirty minutes after administration, wear a cuff and use an unheated non-invasive sphygmomanometer for mice and rats (BLOOD PRESURE MONITOR FOR MICE & RAT Model MK-2000, Muromachi Kikai) to automatically control the caudal artery blood pressure 6 times The average value was measured as the systolic blood pressure before angiotensin I administration. 100 μl of solution B was administered using an intraperitoneal cannula. Two minutes after the administration, the blood pressure was measured in the same manner as the systolic blood pressure after angiotensin I administration. The difference in systolic blood pressure before and after angiotensin I administration was taken as the blood pressure increase value.
図2および図3から明らかなように、納豆菌を用いたマコンブ発酵物に動物体内においてACE阻害活性が認められた。したがって、納豆菌を用いたマコンブ発酵物はACE活性の阻害に有効であることが実証された。As apparent from FIG. 2 and FIG. 3, the ACE inhibitory activity was recognized in the animal body in the fermented macomb using natto. Therefore, it was demonstrated that the fermented macomb using Bacillus natto is effective in inhibiting ACE activity.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013160805A JP6145352B2 (en) | 2013-07-17 | 2013-07-17 | Antihypertensive agent of fermented makonbu using Bacillus natto |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013160805A JP6145352B2 (en) | 2013-07-17 | 2013-07-17 | Antihypertensive agent of fermented makonbu using Bacillus natto |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015021001A JP2015021001A (en) | 2015-02-02 |
JP6145352B2 true JP6145352B2 (en) | 2017-06-07 |
Family
ID=52485754
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013160805A Active JP6145352B2 (en) | 2013-07-17 | 2013-07-17 | Antihypertensive agent of fermented makonbu using Bacillus natto |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6145352B2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6145351B2 (en) * | 2013-07-17 | 2017-06-07 | 濱田 奈保子 | Diabetes condition improver of fermented makonbu using natto bacteria |
JP6301522B1 (en) * | 2017-03-09 | 2018-03-28 | 濱田 奈保子 | Antihypertensive composition and method for producing the same |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5338647A (en) * | 1976-09-20 | 1978-04-08 | Seisaku Kawabata | Method of making fermented soybean with tangle therein |
JPH11276109A (en) * | 1998-03-30 | 1999-10-12 | Oshikiri Shokuhin Kk | Production of fermented soybeans mixed with sea tangle, and production device therefor |
JP2002138100A (en) * | 2000-10-27 | 2002-05-14 | Riken Vitamin Co Ltd | Angiotensin converting enzyme inhibitor |
JP2003128694A (en) * | 2001-10-16 | 2003-05-08 | Riken Vitamin Co Ltd | Angiotensin-converting enzyme inhibitor peptide |
KR101228993B1 (en) * | 2003-09-26 | 2013-02-01 | 바이오메디칼 리서치 그룹 인코포레이티드 | Fermentation and culture method, fermented plant extract, fermented plant extract powder and composition containing the fermented plant extract |
JP2005224233A (en) * | 2004-02-16 | 2005-08-25 | Suetsuna Yoko | Cladosiphon seaweed fermented product by using bacillus natto and use of the same |
JP2006320257A (en) * | 2005-05-19 | 2006-11-30 | Grandhill Osaka:Kk | Seaweed fermented extract, method for producing the extract, and usage of the extract |
JP2009108022A (en) * | 2008-05-01 | 2009-05-21 | Tsujido Kagaku Kk | Therapeutic agent |
TW201018411A (en) * | 2008-11-14 | 2010-05-16 | Zen U Biotechnology Co Ltd | A plant protein product and a method for making the same |
-
2013
- 2013-07-17 JP JP2013160805A patent/JP6145352B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2015021001A (en) | 2015-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101809172B1 (en) | Composition for preventing, improving or treating metabolic disease comprising Akkermansia muciniphila strain or its culture broth cultivated in medium without mucin as effective component | |
JP6684966B2 (en) | Novel Lactobacillus sakei and composition containing the same | |
WO2019203136A1 (en) | Food composition for improving cognitive function, cognitive function improvement agent, and production method thereof | |
JP2009249315A (en) | Mineral absorption promoter, and iron deficiency anemia-ameliorating agent or food composition | |
KR20230152614A (en) | Composition for improving cognitive function speed | |
KR20140017932A (en) | Composition of diabetes-improving effective constituents by fermentation products of the trifoliate orange | |
JP6145352B2 (en) | Antihypertensive agent of fermented makonbu using Bacillus natto | |
JP2014172903A (en) | Agent for suppressing blood pressure increase of sargassum horneri fermentation product using lactobacillus plantarum | |
JP2015017044A (en) | Agent for fat accumulation inhibition and/or fat accumulation amount reduction | |
JP6145353B2 (en) | Antihypertensive agent of fermented hawkfish using Lactobacillus genus | |
WO2016132483A1 (en) | Human chymase inhibitor and drug for preventing and treating disease associated with human chymase activity | |
JP2014181232A (en) | Blood sugar level elevation inhibitor of capsicum frutescens fermentation product using aspergillusoryzae | |
TWI701031B (en) | Composition containing amino acid and cyclic dipeptide | |
JP5848428B2 (en) | Oral pharmaceutical composition and functional food | |
JP2008074734A (en) | Ameliorating agent for insulin resistance | |
JP2014172902A (en) | Diabetic conditions improving agent of sargassum horneri fermentation product using lactobacillus plantarum | |
JP2006016340A (en) | Blood uric acid level reduction agent having extract of punica granatum l. as active ingredient | |
US20220330595A1 (en) | Angiotensin-converting enzyme inhibitor, blood pressure-lowering agent, and beverages and food products | |
JP5749469B2 (en) | Antihypertensive | |
JP2012158578A (en) | Anti-cancer agent | |
WO2021111980A1 (en) | Prophylactic or ameliorating agent for orthostatic hypotension, and composition containing same | |
JP6145351B2 (en) | Diabetes condition improver of fermented makonbu using natto bacteria | |
JPWO2009054360A1 (en) | Visceral fat specific reducing agent | |
JP2012158579A (en) | Food, medical product and animal feed for preventing and ameliorating osteoporosis | |
KR101353943B1 (en) | Composition comprising fermented Dioscorea opposita Thunb. for preventing and treating a gastrointestinal disorder |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160121 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20160121 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20160121 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20160216 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20160216 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160407 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160407 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161025 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20161209 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170221 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20170221 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170425 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170515 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6145352 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |